Chelation therapy with 3,4,3-Li(1,2-HOPO) after pulmonary exposure to plutonium in rats.

[1]  Erin E. Jarvis,et al.  Efficient discrimination of transplutonium actinides by in vivo models† , 2021, Chemical science.

[2]  L. Miccoli,et al.  Chelation Treatment by Early Inhalation of Liquid Aerosol DTPA for Removing Plutonium after Rat Lung Contamination , 2019, Radiation Research.

[3]  G. Deblonde,et al.  Ultra-selective ligand-driven separation of strategic actinides , 2019, Nature Communications.

[4]  L. Miccoli,et al.  Decorporation Approach after Rat Lung Contamination with Plutonium: Evaluation of the Key Parameters Influencing the Efficacy of a Protracted Chelation Treatment , 2017, Radiation Research.

[5]  Erin E. Jarvis,et al.  From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. , 2017, Chemico-biological interactions.

[6]  L. Miccoli,et al.  Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action , 2016, Radiation Research.

[7]  Deborah I. Bunin,et al.  Biodistribution of the Multidentate Hydroxypyridinonate Ligand [14C]‐3,4,3‐LI(1,2‐HOPO), a Potent Actinide Decorporation Agent , 2015, Drug development research.

[8]  S. Gauny,et al.  238Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice , 2014, International journal of radiation biology.

[9]  Deborah I. Bunin,et al.  Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimen , 2013, Radiation research.

[10]  Erin E. Jarvis,et al.  Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions , 2013, Toxicology mechanisms and methods.

[11]  N. Tsapis,et al.  Decorporation Approach Following Rat Lung Contamination with a Moderately Soluble Compound of Plutonium Using Local and Systemic Ca-DTPA Combined Chelation , 2012, Radiation research.

[12]  Erin E. Jarvis,et al.  Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example , 2012 .

[13]  Z. Kazzi,et al.  Calcium and zinc DTPA administration for internal contamination with plutonium-238 and americium-241. , 2012, Current Pharmaceutical Biotechnology.

[14]  D. Renault,et al.  Plutonium behavior after pulmonary administration according to solubility properties, and consequences on alveolar macrophage activation. , 2012, Journal of radiation research.

[15]  P. Ravi,et al.  Radioanalytical determination of plutonium and americium using ion exchange and extraction chromatography technique in urine , 2011 .

[16]  K. Raymond,et al.  Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators , 2011, Hemoglobin.

[17]  Deborah I. Bunin,et al.  Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). , 2010, Health physics.

[18]  N. Tsapis,et al.  Preferential Decorporation of Americium by Pulmonary Administration of DTPA Dry Powder after Inhalation of Aged PuO2 Containing Americium in Rats , 2010, Radiation research.

[19]  É. Blanchardon,et al.  Absorption of plutonium compounds in the respiratory tract , 2010, Journal of radiological protection : official journal of the Society for Radiological Protection.

[20]  S. Krivovichev,et al.  Actinides in Animals and Man , 2010 .

[21]  P. Durbin.  LAURISTON S. TAYLOR LECTURE: THE QUEST FOR THERAPEUTIC ACTINIDE CHELATORS , 2008, Health physics.

[22]  P. Bérard,et al.  Autorisation de mise sur le marché du Ca-DTPA , 2008 .

[23]  C. Auwer,et al.  Review of actinide decorporation with chelating agents , 2007 .

[24]  Jiwang Chen,et al.  Alveolar type I cells protect rat lung epithelium from oxidative injury , 2006, The Journal of physiology.

[25]  J. Delforge,et al.  Comparative tissue uptake and cellular deposition of three different plutonium chemical forms in rats , 2004, International journal of radiation biology.

[26]  Jide Xu,et al.  Rational design of sequestering agents for plutonium and other actinides. , 2003, Chemical reviews.

[27]  B. Muggenburg,et al.  Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX. , 2003, Radiation protection dosimetry.

[28]  P. Durbin,et al.  Octadentate hydroxypyridinonate (HOPO) ligands for plutonium (i.v.): pharmacokinetics and oral efficacy. , 2003, Radiation protection dosimetry.

[29]  Jide Xu,et al.  Synthesis and initial evaluation for in vivo chelation of Pu(IV) of a mixed octadentate spermine-based ligand containing 4-carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone and 6-carbamoyl-1-hydroxy-2(1H)-pyridinone. , 2002, Journal of medicinal chemistry.

[30]  P. Durbin,et al.  Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. , 2000, International journal of radiation biology.

[31]  P. Durbin,et al.  Development of Decorporation Agents for the Actinides , 1998 .

[32]  P. Durbin,et al.  Chelation therapy by DFO-HOPO and 3,4,3-LIHOPO for injected Pu-238 and Am-241 in the rat: effect of dosage, time and mode of chelate administration. , 1996, International journal of radiation biology.

[33]  P. Durbin,et al.  Treatment with 3,4,3-LIHOPO of simulated wounds contaminated with plutonium and americium in rat. , 1996, International journal of radiation biology.

[34]  H. Métivier,et al.  Efficacy of 3,4,3-LIHOPO for enhancing the excretion of plutonium from rat after simulated wound contamination as a tributyl-n-phosphate complex. , 1995, International journal of radiation biology.

[35]  P. Durbin,et al.  Reduction of the Retention of 238Pu Inhaled as the Tributylphosphate Complex in Rats Treated by 3,4,3-LIHOPO , 1994 .

[36]  P. Durbin,et al.  Removal of Plutonium and Americium from the Rat Using 3,4,3-LIHOPO and DTPA after Simulated Wound Contamination: Effect of Delayed Administration and Mass of Plutonium , 1994 .

[37]  K. Moutairou,et al.  Comparative toxicity of 3,4,3-lihopo and DTPA in baboons: preliminary results , 1994 .

[38]  P. Durbin,et al.  Efficacy of 3,4,3-LIHOPO for reducing the retention of 238Pu in rat after inhalation of the tributyl phosphate complex. , 1993, International journal of radiation biology.

[39]  P. Durbin,et al.  Comparative efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat after simulated wound contamination as nitrates. , 1993, International journal of radiation biology.

[40]  P. Durbin,et al.  Early chelation therapy for injected Pu-238 and Am-241 in the rat: comparison of 3,4,3-LIHOPO, DFO-HOPO, DTPA-DX, DTPA and DFOA. , 1993, International journal of radiation biology.

[41]  M. Ellender,et al.  The efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat: comparison with other siderophore analogues. , 1992, International journal of radiation biology.

[42]  M. Bhattacharyya,et al.  Guidebook for the treatment of accidental internal radionuclide contamination of workers , 1992 .

[43]  W. Sontag.  Microdistribution of 239Pu in the rat skeleton. Part I. Dose dependency. , 1991, International journal of radiation biology.

[44]  P. Durbin,et al.  Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. , 1988, Journal of medicinal chemistry.

[45]  A. Hodgson,et al.  Use of DTPA for Increasing the Rate of Elimination of Plutonium-238 and Americium-241 from Rodents after their Inhalation as the Nitrates , 1985, Human toxicology.

[46]  A. Lennox,et al.  Decorporation of inhaled plutonium nitrate from hamsters using Zn-DTPA. , 1984, Health physics.

[47]  A. James,et al.  Decorporation of 238PuO2 from the hamster by inhalation of chelating agents. , 1982, Health physics.

[48]  G. Hook,et al.  Plasma proteins of the bronchoalveolar surface of the lungs of smokers and nonsmokers. , 2015, The American review of respiratory disease.

[49]  J. Stather,et al.  The use of Puchel and DTPA for removing 238PuO2 from the lungs of hamsters. , 1981, Health physics.

[50]  C. W. Jones,et al.  Dependency of chelation efficacy upon time after first DTPA injection. , 1979, Radiation research.

[51]  R. Guilmette,et al.  Toward an optimal DTPA therapy for decorporation of actinides: time-dose relationships for plutonium in the dog. I. , 1979, Radiation Research.

[52]  P. Durbin,et al.  Plutonium deposition kinetics in the rat. , 1972, Health physics.